ReviewEuropean journal of clinical pharmacology2026
Circadian considerations in antimicrobials.
Review in European journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sleep, circadian rhythms and outcomes in intensive care unit.Frontiers in neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCircadian rhythms regulate key physiological processes, including metabolism, immune function, and organ perfusion, which can influence antimicrobial pharmacokinetics and, in turn, may indirectly shape pharmacodynamic outcomes through changes in drug exposure or host immune responses. This review examines the evidence supporting circadian effects on antimicrobial efficacy and toxicity and evaluates the potential clinical relevance of time-of-day dosing.
methodsWe conducted a narrative review of 84 experimental and clinical studies published up to November 2025, identified through PubMed and Scopus. Eligible studies evaluated time-of-day or circadian effects on antimicrobial pharmacokinetics, safety, efficacy, or host immune response across major antibacterial, antiviral, antifungal, and antiparasitic drug classes.
resultsCircadian variation in gastric motility, hepatic metabolism, and renal clearance can alter antimicrobial exposure independent of dose. The most consistent circadian associations relate to toxicity: aminoglycoside and amphotericin B nephrotoxicity are more frequent with rest-phase dosing, while fluoroquinolone-associated QT prolongation is greater with afternoon administration, suggesting a relative safety advantage with morning dosing. Evidence for circadian modulation of antimicrobial efficacy is limited and heterogeneous, with observed effects more plausibly explained by variations in drug exposure, host immunity, or particularly in parasitic infections-pathogen developmental stage rather than intrinsic circadian changes in pathogen susceptibility. For many antivirals and antifungals, long half-lives and fixed dosing schedules minimize the clinical impact of dosing time.
conclusionOverall, circadian regulation may influence antimicrobial pharmacology and toxicity in selected settings, although the available evidence is heterogeneous and clinical validation remains limited.
Indexed as
Identifiers
41649575What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.